Mahendra Deonarain

Current Organisation: ANTIKOR BIOPHARMA LIMITED
(some projects in the list below may not be associated with this organisation)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£499,155

Mar 23 - Sep 24

Harnessing FDC technology for metastatic colorectal cancer (mCRC)

Innovate UK award to ANTIKOR BIOPHARMA LIMITED and Mahendra Deonarain

£1,242,164

Mar 22 - Mar 24

Advanced preclinical development of a solid tumour-tailored gastric cancer therapy

Innovate UK award to ANTIKOR BIOPHARMA LIMITED and Mahendra Deonarain

£74,963

May 20 - Feb 21

Accelerated Coronavirus clearance immunotherapy

Innovate UK award to ANTIKOR BIOPHARMA LIMITED and Mahendra Deonarain

£120,300

May 20 - Feb 21

Gastric Cancer Antibody Fragment Drug Conjugate: Promising candidate to manufacturable product (Continuation)

Innovate UK award to ANTIKOR BIOPHARMA LIMITED and Mahendra Deonarain

£349,466

Dec 19 - May 21

Gastric Cancer Antibody Fragment Drug Conjugate: Promising candidate to manufacturable product

Innovate UK award to ANTIKOR BIOPHARMA LIMITED and Mahendra Deonarain

£365,629

Feb 19 - Jul 20

Improved Linkers for Antibody Fragment Drug Conjugates

Innovate UK award to ANTIKOR BIOPHARMA LIMITED and Mahendra Deonarain

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}